Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Am J Reprod Immunol. 2011 Jan 18;65(6):597–609. doi: 10.1111/j.1600-0897.2010.00968.x

Fig. 6.

Fig. 6

Model of differential T cell stimulation following NP-mediated TAA delivery. DC loaded with sub-optimal antigen forms (such as soluble tumor lysate- left panel) result in T cell stimulation reactions which lead to anergy or tolerance, and are unable to overcome negative signals in the tumor micro-environment. NP-mediated delivery of Ag, in contrast, leads to DC activation and production of pro-inflammatory/Th1 cytokines which can activate quiescent or tolerized anti-tumor T cells (right panel), potentially overcoming tumor tolerance. NPL-mediated Ag delivery would therefore represent an new and promising methodology for increasing the potency of DC-based anti-tumor vaccination schema in ovarian cancer.